Advertisement
 
YOU ARE HERE: LAT HomeCollectionsDiagnostic Tests
IN THE NEWS

Diagnostic Tests

NEWS
October 11, 1994 | From Associated Press
A diagnostic test for cancer that could revolutionize screening for the deadly disease has been developed by researchers at Johns Hopkins Medical Institutions. The new test, reported in today's issue of Proceedings of the National Academy of Science, identifies replication errors in DNA that occur frequently in cancer. The errors, known as clonal markers, are used as a fingerprint for cancer.
Advertisement
WORLD
June 20, 2003 | Tyler Marshall, Times Staff Writer
Amid signs that the world's first SARS outbreak may have run its course, a leading World Health Organization official warned Thursday that detecting any recurrence of the pneumonia-like disease next winter will pose an entirely new set of medical challenges. Those stricken with severe acute respiratory syndrome initially carry an extremely low level of the virus, making an immediate diagnosis all but impossible, said the WHO's senior communicable diseases specialist, David Heymann.
HEALTH
August 16, 2004 | Linda Marsa, Special to The Times
Ovarian cancer is uncommonly deadly. Tumors aren't usually detected until the disease has spread beyond the ovaries, at which point only a third of patients survive more than five years. A promising blood test could change this bleak picture, enabling doctors to identify ovarian cancer at its earliest, most treatable stage. "This has the potential of being an important advance," says Dr. Philip DiSaia, director of gynecological oncology at the UC Irvine School of Medicine.
BUSINESS
June 10, 1994
* Thomas Witty has joined Viratek Inc., the Costa Mesa drug development company, as director of diagnostic research. Witty's work will focus on developing diagnostic tests for genetic diseases. Witty was most recently with Biocircuits Corp. in the San Francisco Bay Area.
BUSINESS
November 3, 1999 | From Associated Press
Abbott Laboratories Inc., the nation's largest maker of medical diagnostic tests, agreed Tuesday to pay a $100-million fine and stop selling more than 100 products until it corrects repeated violations of federal quality rules. The company's violations date to 1993, said the Food and Drug Administration, which sought a consent decree to settle the issue because Abbott did not correct the problems despite six years of government inspections and warnings.
Los Angeles Times Articles
|